By Sophie Barret – Hifas da Terra & Patrick Holford
Two medicinal mushrooms are particularly relevant when it comes to optimising your brain health, here we discuss Reishi (Ganoderma Lucidum) and Lion’s Mane (Hericium erinaceus); in terms of their potency and use in both Alzheimer’s and Dementia as well as the studies and clinical research into both these significant strains.
Alzheimer’s disease is the most common form of dementia and, according to the WHO, accounts for 60-70% of cases. It is a progressive neurological disorder that involves a steady decline in thinking, behaviour and social skills that affects a person’s ability to live independently. Although age is the main risk factor for dementia, the disease is not an inevitable consequence of ageing. This type of dementia does not exclusively affect older people. Early-onset dementia (onset of symptoms before the age of 65) accounts for up to 9% of cases. Regular physical and mental exercise, avoiding cigarette smoke and alcohol, controlling weight and blood pressure, as well as following a healthy diet and premium quality supplementation can reduce the risk of Alzheimer’s or even slow down the process.
The application of Mycotherapy for Alzheimer’s focuses on the use of pure, standardised, organic extracts of Lion’s Mane (Hericium erinaceus) and Reishi (Ganoderma lucidum), the supplementation of which has been associated in clinical studies with a reduction in the likelihood of mild cognitive impairment and in vivo with anti-dementia activity in cognitive deficits.
Lion’s Mane, (Hericium erinaceus) is a medicinal mushroom with diverse pharmacological activities in the prevention of many age-associated neurological dysfunctions, including Alzheimer’s disease and Parkinson’s disease. (5). Supplementation of H. erinaceus has been shown to improve cognitive function and memory in people with mild cognitive impairment (4) and slow cognitive decline and dementia. Its extract is highly recommended in the treatment of neurodegenerative diseases.
The action of Lion’s Mane is based both on its ability to regenerate damaged nerve axons and to enhance myelinization. This is thanks to the rich content of hericenones found in Lion’s mane extract that act as a Nerve Growth Factor (NGF) enhancing agent.
European Biotech, Hifas da Terra, conducted the Neurofood study in people using a unique Lion’s Mane strain. The results showed significant improvements in participants’ attention, memory, concentration, processing speed and visuospatial skills.
Reishi has demonstrated neuroprotective capacity due to its potent antioxidant properties. Thanks to the antioxidant capacity of G. lucidum’s active biomolecules, especially terpenes such as ganoderic acid, it can improve the reduction of age-related oxidation linked to impaired cognitive function (12,13,14), alleviating neuronal damage and inhibiting apoptosis in Alzheimer’s disease (15).
Several studies and reviews have demonstrated its preventive and therapeutic effect on neuronal damage and cognitive impairment (9).
The antioxidant effect of G. lucidum, thanks to the ability of its active ingredients to scavenge free radicals, may enhance the reduction of age-related oxidation linked to cognitive function decline. (10).
One of the hottest areas of brain research is the effects of various hallucinogenic compounds, notably psilocybin – a hallucinogenic substance in certain types of mushrooms, but also LSD and the Amazonian plant potion Ayahuasca, a rich source of DMT, on mental health and brain function. These compounds are tryptamines and share a quality of activating a key receptor site in the brain for serotonin, called 5-HT2 receptors. As a group, they are all shown to be potential promoters of neuroregeneration and neuroplasticity, helping make neuron connections and perhaps new neurons. They also stimulate brain-derived neurotrophic factor (BDNF), a key brain signaller that stimulates growth.
With many studies (13) now showing the potential of psychedelics to help those with treatment-resistant depression, drug addiction and also anxiety in terminal patients, much attention is being focussed on what they actually do in the brain. On a psychological level, breakthroughs in debilitating depression and anxiety seem to occur through the experience of patients ‘exorcising the demons’ of early traumas through psychotherapy assisted trips. But there may be more going on at a biological level. Also, studies are underway testing less heroic doses – microdoses – of these agents. It is too early to say whether they could have a helpful role in those with early cognitive decline and brain shrinking but it is certainly plausible and an area of ongoing research. It’s a case of ‘watch this space’.
In summary, the application of Mycotherapy for any type of dementia seeks to provide a neuroprotective effect, improving quality of life. It focuses also on the use of pure, standardised organic extracts of Lion’s Mane (Hericium erinaceus) and Reishi (Ganoderma lucidum), the supplementation of which has been associated in clinical studies with a reduction in the probability of suffering mild cognitive impairment (MCI) and in vivo with anti-dementia activity in cognitive deficits.
Lion’s Mane, (Hericium erinaceus) is a medicinal mushroom with a variety of pharmacological activities in preventing many age-associated neurological dysfunctions, including Alzheimer’s and Parkinson’s (1). As mentioned, supplementation of H. erinaceus (Lion’s Mane) has been shown to improve cognitive function and memory in people with mild cognitive impairment (2) and is therefore highly recommended in the integrative treatment of neurodegenerative diseases.
The action of H. erinaceus is based both on its ability to regenerate myelin and to regenerate new synapses thanks to its content of hericenones and erinacines, which act as Nerve Growth Factor (NGF) enhancing agents, both at the level of expression and secretion. This contribution of Hericium erinaceus has been shown to both prevent (5) and slow cognitive decline and dementia, as well as showing neuroprotective effects.
Several studies and reviews have also demonstrated as mentioned the neuroprotective capacity of Reishi, (Ganoderma lucidum), as well as its preventive and therapeutic effect on neuronal damage and cognitive impairment (9). While other studies have demonstrated its antioxidant effect concluding that, thanks to the ability of its active ingredients to scavenge free radicals, can enhance the reduction of age-related oxidation linked to the (10)
If you are going to consider two medicinal mushrooms for both these conditions these are the two medicinal mushrooms with the most scientific research behind them.
Want to learn more about how medicinal mushrooms can support you brain and mental health? Join us for the Mushrooms & the Mind webinar!
Thank you for reading!
Food for the Brain is a non-for-profit educational and research charity that offers a free Cognitive Function Test and assesses your Dementia Risk Index to be able to advise you on how to dementia-proof your diet and lifestyle.
By completing the Cognitive Function Test you are joining our grassroots research initiative to find out what really works for preventing cognitive decline. We share our ongoing research results with you to help you make brain-friendly choices.
Please support our research by becoming a Friend of Food for the Brain.
1. Li IC, Chang HH, Lin CH, et al. Prevention of Early Alzheimer’s Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. Front Aging Neurosci. 2020;12:155. Published 2020 Jun 3. doi:10.3389/fnagi.2020.00155.
2. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T (2009) Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research 23, 367-372.
3. Kim, Y. O., Lee, S. W., & Kim, J. S. (2014). A comprehensive review of the therapeutic effects of Hericium erinaceus in neurodegenerative disease. Journal of Mushroom, 12(2), 77-81.
4. Mori K, Obara Y, Hirota M, Azumi Y, Kinugasa S, Inatomi S, Nakahata N (2008) Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biologicaland Pharmaceutical Bulletin 31, 1727-1732.
5. Li IC, Lee LY, Tzeng TT, et al. Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines. Behav Neurol. 2018;2018:5802634. Published 2018 May 21. doi:10.1155/2018/5802634.
6. Kawagishi, H., Zhuang, C., & Yunoki, R. (2008). Compounds for dementia from Hericium erinaceum. Drugs of the Future, 33(2), 149.
7. Ma BJ, Shen JW, Yu HY, Ruan Y, Wu TT, Zhao X (2010) Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus. Mycology 1,
8. Moldavan M, Grygansky AP, Kolotushkina OV, Kirchhoff B, Skibo GG, Pedarzani P (2007) Neurotropic and trophic action of Lion’s Mane mushroom Hericium erinaceus (Bull.: Fr.) Pers. (Aphyllophoromycetideae) extracts on nerve cells in vitro. International Journal of Medicinal Mushrooms 9, 15-28.
9. Yu, N., Huang, Y., Jiang, Y., Zou, L., Liu, X., Liu, S., … & Zhu, Y. (2020). Ganoderma lucidum triterpenoids (GLTs) reduce neuronal apoptosis via inhibition of ROCK signal pathway in APP/PS1 transgenic Alzheimer’s disease mice. Oxidative medicine and cellular longevity,
10. Huang, S., Mao, J., Ding, K., Zhou, Y., Zeng, X., Yang, W., … & Pei, G. (2017). Polysaccharides from Ganoderma lucidum promote cognitive function and neural progenitor proliferation in mouse model of Alzheimer’s disease. Stem cell reports, 8(1), 84-94.
11. Klaus AS, Kozarski MS, Nikšić MP (2011) Antioxidant properties of hot water extracts from carpophore and spores of mushroom Ganoderma lucidum. Proceedings for Natural Science, Matica Srpska Novi Sad 120, 277-286.
12. ozarski MS, Klaus AS, Nikšić MP (2011) Extract from wild strain of mushroom Ganoderma lucidum as natural antioxidant. Proceedings for Natural Science, Matica Srpska Novi Sad 120, 287-295.
13. Saeger HN, Olson DE. Psychedelic-inspired approaches for treating neurodegenerative disorders. J Neurochem. 2022 Jul;162(1):109-127. doi: 10.1111/jnc.15544. Epub 2021 Dec 5. PMID: 34816433; PMCID: PMC9126991.
